• Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting, November 11-14, 2020

    "Development of improved small molecule STING agonists suitable for systemic administration"

    PDF Download
  • AACR Virtual Annual Meeting II, June 22-24, 2020

    "Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance"

    PDF Download
  • "In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist"

    PDF Download
  • "Development of selective small molecule STING agonists suitable for systemic administration"

    PDF Download
  • "Development and characterization of small molecule HPK1 inhibitors"

    PDF Download
  • "Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors"

    PDF Download
  • Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020

    “A First-in-human study of SEL120, a novel oral selective CDK8/19 inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome”

    PDF Download
  • "Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in Patients with Acute Myeloid Leukemia"

    PDF Download
  • Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes, Biomolecules 2020

    Podkalicka, P.; Mucha, O.; Kruczek, S.; Biela, A.; Andrysiak, K.; Stępniewski, J.; Mikulski, M.; Gałęzowski, M.; Sitarz, K.; Brzózka, K.; Józkowicz, A.; Dulak, J.; Łoboda, A. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes. Biomolecules 2020, 10, 143.

    PDF Download
  • 61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL, USA

    "SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial"

    PDF Download
  • "CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation"

    PDF Download
  • Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019), November 6–10, National Harbor, MD, USA

    "Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro characterization"

    PDF Download
  • "Development and characterization of next generation small molecule STING agonists"

    PDF Download
  • CICON 2019 – Translating Science into Survival – September 25-28, 2019, Paris, France

    “Characterization of novel potent dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy”

    PDF Download
  • 24th Congress of EHA, June 13-16, 2019 Amsterdam, Netherlands

    "CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"

    PDF Download
  • ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA

    "CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"

    PDF Download
  • AACR Annual Meeting 2019, March 29- April 3, 2019, Atlanta, GA, USA

    "SEL120, a Potent and Specific Inhibitor of CDK8 Induces Complete Remission in Human Patient Derived Xenograft Models of Acute Myeloid Leukemia (AML)"

    PDF Download
  • "Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro and in vivo characterization"

    PDF Download
  • "Discovery and characterization of next-generation small molecule direct STING agonists"

    PDF Download
  • American Society of Hematology (ASH) Annual Meeting, 1-4 December 2018, San Diego, CA, USA

    "CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human AML Models"

    PDF Download
  • EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 13-16 November 2018, Dublin, Ireland

    “SEL120−34A, a potent and specific inhibitor of CDK8, as a potential treatment of acute myeloid and lymphoblastic leukemias”

    PDF Download
  • Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), 7-11 November 2018, Washington, DC, USA

    "Novel class of small molecule direct STING agonists as a potential cancer immunotherapy"

    PDF Download
  • “Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

    PDF Download
  • Mechanisms to Therapies: Innovations in Cancer Metabolism, 9-11 October 2018, Bilbao, Spain

    "Discovery of novel SHMT1/2 small molecule inhibitors for cancer treatment"

    PDF Download
  • Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice, 3-5 October 2018, Dubrovnik, Croatia

    “CDK8 inhibitor SEL120 targets AML by regulation of transcriptional programs involved in the maintenance of leukemia stem cells”

    PDF Download
  • Annual Immuno-Oncology Summit, 27-31 August 2018, Boston, MA, USA

    "Discovery of novel small molecule STING agonists as a new cancer immunotherapy"

    PDF Download
  • “Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

    PDF Download
  • AACR Annual Meeting 2018, 14-18 April 2018, Chicago, IL, USA

    "Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy"

    PDF Download
  • "CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of transcriptional programs involved in the maintenance of leukemia stem cells"

    PDF Download
  • "Discovery of novel SHMT small molecule inhibitors for cancer treatment"

    PDF Download
  • AACR Annual Meeting 2017, 1 - 5 April 2017, Washington, DC, USA

    "Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells"

    PDF Download
  • "Differential activity on lung adenocarcinoma cells with loss-of-function mutations of SWI/SNF protein SMARCA4"

    PDF Download
  • "Small molecule inhibitors of SHMT1/2 validate serine metabolism as a target in the treatment of c-Myc positive solid tumors"

    PDF Download
  • "Inhibition of CDK8 kinase with SEL120-34A allows for a personalized approach in AML"

    PDF Download
  • "Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies"

    PDF Download
  • AACR Annual Meeting 2015, 18 – 22 April 2015 in Philadelphia, PA, USA:

    “First-in-class dual PIM/FLT3 inhibitor SEL24-B489 for the treatment of hematological malignancies”

    PDF Download
  • “Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer”

    PDF Download
  • AACR Annual Meeting 2014, 5-9 April 2014, San Diego, USA:

    “Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies”

    PDF Download
  • “Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases”

    PDF Download